ChromaDex Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

ChromaDex wird ein Gewinn- und Umsatzwachstum von 106.1% bzw. 18% pro Jahr prognostiziert, während der Gewinn pro Aktie um 105.1% pro Jahr wachsen soll.

Wichtige Informationen

102.9%

Wachstumsrate der Gewinne

100.5%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.1%
Wachstumsrate der Einnahmen	18.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Jul 25

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Jun 05

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CDXC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	134	13	13	15	2
12/31/2025	113	6	9	14	4
12/31/2024	95	1	3	6	5
6/30/2024	86	-1	1	1	N/A
3/31/2024	83	-4	5	5	N/A
12/31/2023	84	-5	7	7	N/A
9/30/2023	83	-6	6	6	N/A
6/30/2023	81	-6	2	2	N/A
3/31/2023	77	-11	-6	-5	N/A
12/31/2022	72	-17	-15	-15	N/A
9/30/2022	69	-20	-20	-20	N/A
6/30/2022	69	-28	-22	-22	N/A
3/31/2022	70	-27	-26	-26	N/A
12/31/2021	67	-27	-25	-24	N/A
9/30/2021	65	-28	-20	-19	N/A
6/30/2021	62	-23	-17	-17	N/A
3/31/2021	60	-21	-11	-11	N/A
12/31/2020	59	-20	-11	-11	N/A
9/30/2020	57	-23	-12	-11	N/A
6/30/2020	55	-26	-16	-15	N/A
3/31/2020	51	-30	-23	-23	N/A
12/31/2019	46	-32	-21	-20	N/A
9/30/2019	42	-32	-26	-25	N/A
6/30/2019	38	-33	-23	-22	N/A
3/31/2019	35	-33	-22	-20	N/A
12/31/2018	32	-33	-22	-21	N/A
9/30/2018	30	-34	-21	-20	N/A
6/30/2018	28	-29	-17	-15	N/A
3/31/2018	24	-23	N/A	-14	N/A
12/30/2017	21	-17	N/A	-10	N/A
9/30/2017	18	-10	N/A	-6	N/A
7/1/2017	16	-8	N/A	-6	N/A
4/1/2017	18	-6	N/A	0	N/A
12/31/2016	22	-4	N/A	-3	N/A
10/1/2016	22	-3	N/A	-4	N/A
7/2/2016	24	-2	N/A	-5	N/A
4/2/2016	24	-1	N/A	-4	N/A
1/2/2016	18	-3	N/A	-2	N/A
10/3/2015	22	-3	N/A	-2	N/A
7/4/2015	20	-3	N/A	-1	N/A
4/4/2015	18	-5	N/A	-2	N/A
1/3/2015	15	-5	N/A	-3	N/A
9/27/2014	13	-5	N/A	-4	N/A
6/28/2014	12	-5	N/A	-4	N/A
3/29/2014	11	-5	N/A	-5	N/A
12/28/2013	10	-4	N/A	-4	N/A
9/28/2013	11	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CDXC wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).

Ertrag vs. Markt: CDXC wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CDXC wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CDXCDie Einnahmen des Unternehmens (18% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: CDXCDie Einnahmen des Unternehmens (18% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CDXC in 3 Jahren voraussichtlich hoch sein wird

ChromaDex Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.6% to US$6.54

Forecast breakeven date moved forward to 2024

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

Consensus EPS estimates fall from profit to US$0.008 loss

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

Price target increased by 9.6% to US$6.28

Recent updates

Chromadex Corporation Announces Chief Financial Officer Changes

Independent Director notifies of intention to sell stock

ChromaDex Corporation announced that it expects to receive $32.058489 million in funding

Price target increased by 7.6% to US$6.54

Forecast breakeven date moved forward to 2024

Second quarter 2024 earnings released: EPS: US$0 (vs US$0.029 loss in 2Q 2023)

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

ChromaDex Corporation to Report Q2, 2024 Results on Aug 07, 2024

ChromaDex Corporation Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Corp Shares Results from a Milestone Phase II Clinical Study Showing the Promising Effects of Nicotinamide Riboside (NR) Supplements for People with Peripheral Artery Disease

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen®

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

New major risk - Share price stability

Consensus EPS estimates fall from profit to US$0.008 loss

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 9.6% to US$6.28

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Corporation to Report Q1, 2024 Results on May 08, 2024

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

New minor risk - Share price stability

Consensus EPS estimates have been upgraded.

Price target increased by 13% to US$5.53

Price target decreased by 9.3% to US$4.94

Full year 2023 earnings: EPS exceeds analyst expectations

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation to Report Q4, 2023 Results on Mar 06, 2024

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+

Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)

Chromadex Corp. Shares Results from Phase II Clinical Study

Consensus EPS estimates upgraded to US$0.088 loss

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 11% to US$4.88

ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)

ChromaDex Corporation to Report Q3, 2023 Results on Nov 08, 2023

ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

New minor risk - Market cap size

Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside

Consensus EPS estimates upgraded to US$0.12 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q2, 2023 Results on Aug 09, 2023

ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD) in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Full Year 2023

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS misses analyst expectations

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Chromadex Corporation Names Brianna Gerber Chief Financial Officer

Forecast to breakeven in 2025

ChromaDex Corporation Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside Increase Nicotinamide Adenine Dinucleotide Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Chromadex Corp. Reports FDA’S Conclusion That Nicotinamide Mononucleotide (Nmn) May Not Be Sold or Marketed as A Dietary Supplement in the United States

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChromaDex Corporation Provides Earnings Guidance for the Year 2022

ChromaDex Corporation to Report Q3, 2022 Results on Nov 02, 2022

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Chromadex Shares Promising Findings from Clinical Study Showcasing The Safety and Tolerability of Nicotinamide Riboside (Nr) in Heart Failure with Reduced Ejection Fraction

Insider recently bought US$1.2m worth of stock

ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale

ChromaDex in pact to introduce anti-aging compound in Brazil

Ayana Bio appoints Frank Jaksch as CEO